2022 Fiscal Year Final Research Report
A new glucose-responsive injectable hydrogel for mesenchymal stem cells transplantation to rat myocardial infarction heart
| Project/Area Number |
21K20526
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
0403:Biomedical engineering and related fields
|
|---|
| Research Institution | National Cardiovascular Center Research Institute |
|---|
Principal Investigator |
Le Hue Thi 国立研究開発法人国立循環器病研究センター, 研究所, リサーチフェロー (80906280)
|
|---|
| Project Period (FY) |
2021-08-30 – 2023-03-31
|
| Keywords | injectable hydrogel / myocardial infarction / sorbitol response / adverse remodeling / MSCs / material distribution / material retention / cardiac function |
|---|
| Outline of Final Research Achievements |
A new sugar-responsive injectable hydrogel was developed for the treatment of myocardial infarction by combining it with or without mesenchymal stem cells (MSCs). We achieved the proof-of-concept in which the material solution included poly (3-acrylamidophenylboronic acid-co-acrylamide) (BAAm), poly(vinyl alcohol) (PVA), and sorbitol can become an in-situ gel after injection into the tissue via simple diffusion of the sorbitol to surrounding tissue. It has been found that those materials have no cytotoxicity with several cell types involving MSCs, smooth muscle cells, and fibroblast cells. Using a myocardial infarction model, we demonstrated that intramyocardial injection of this material prevents adverse cardiac remodeling, resulting in preserved cardiac function. The current data was published in a peer-reviewed journal and presented at six domestic and international scientific conferences.
|
| Free Research Field |
biomaterial
|
| Academic Significance and Societal Importance of the Research Achievements |
The findings of this study suggest that sorbitol-responsive injectable hydrogel may be a novel therapeutic approach for myocardial infarction. Moreover, this study proposes a material concept that may surmount the low retention of cells and drugs to the target tissue.
|
